Earnings call transcript: Lineage Cell rises on Q3 2026 pipeline update

Lineage Cell Therapeutics reported a sharp decline in Q3 2026 revenue, falling to $1.5 million from $3.7 million the previous year. The company's net income improved to $4.2 million, or $0.02 per share, after a $28 million loss in the same period last year. This profit improvement was primarily due to a non-cash warrant remeasurement tied to a lower share price, rather than stronger operational performance.

The company's cash position is strong, with $45.2 million in cash, equivalents and marketable securities as of September 30, 2026, providing a runway into Q2 2028. Lineage has expanded its pipeline, adding three new allogeneic cell transplant campaigns: OpRegen, OPC1 and HUNT1. The HUNT1 Huntington's disease program was acquired from NeuroAirmid Therapeutics, immediately expanding the company's clinical portfolio.

Despite the improved metrics, the company's operating expenses rose 17.3% to $8.8 million, and research and general administrative costs increased 16.7% to $4.9 million. No earnings forecast was provided alongside the quarterly results, making it difficult to measure the results against published revenue or EPS targets. The stock was recently quoted at $0.805, up 1.9% from the previous close of $0.79, indicating investor caution and a modest reaction to the update.